BioNTech guides for worse-than-expected 2025 revenue decline
German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ...
Hosted on MSN10d
German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent
DUESSELDORF, Germany (Reuters) -A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 ...
BioNTech initiated with a Buy at Citi
Citi analyst Geoff Meacham initiated coverage of BioNTech (BNTX) with a Buy rating and $145 price target Healthcare policy remains a key ...
Investopedia5d
BioNTech Stock Drops as Sales Outlook Disappoints
U.S.-listed shares of BioNTech fell Monday, as the COVID-19 vaccine maker’s soft sales outlook offset better-than-expected quarterly results. The German company said it expects 2025 total ...
BioNTech reports Q4 EPS EUR 1.08 vs. EUR 1.88 last year
Reports Q4 revenue EUR 1.19B vs. EUR 1.48B last year. “From the very beginning, BioNTech’s (BNTX) vision has been to translate our science into ...